<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Biology and physiology of thrombopoietin
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Biology and physiology of thrombopoietin
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Biology and physiology of thrombopoietin
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David J Kuter, MD, DPhil
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lawrence LK Leung, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer S Tirnauer, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 29, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thrombopoietin (TPO) is the physiologically relevant regulator of platelet production. Although the concept of a platelet growth factor analogous to erythropoietin had been proposed in the 1950s, it was not until 1994 that the existence of this hematopoietic growth factor was demonstrated and the protein purified [
         <a href="#rid1">
          1-5
         </a>
         ]. Although historically called "thrombopoietin" [
         <a href="#rid6">
          6
         </a>
         ], its discoverers also called it by several other names, including megapoietin [
         <a href="#rid3">
          3
         </a>
         ], megakaryocyte growth and development factor (MGDF) [
         <a href="#rid4">
          4
         </a>
         ], and c-Mpl ligand [
         <a href="#rid2">
          2
         </a>
         ]. The last name is often used instead of TPO because the receptor for TPO, called c-Mpl, was discovered prior to the identification of TPO [
         <a href="#rid7">
          7
         </a>
         ] and was instrumental in helping to purify the ligand (ie, the c-Mpl ligand) that bound to it.
        </p>
        <p>
         This topic will review the biology and physiology of TPO. The potential clinical applications of TPO, ranging from the management of thrombocytopenic states to improving yields from platelet apheresis, are discussed separately [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6671.html" rel="external">
          "Clinical applications of thrombopoietic growth factors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          STRUCTURE OF THROMBOPOIETIN
         </span>
         <span class="headingEndMark">
          —
         </span>
         TPO is produced primarily in liver parenchymal cells with much smaller amounts being made in the kidney and bone marrow [
         <a href="#rid9">
          9,10
         </a>
         ]. It is synthesized as a 353 amino acid precursor protein with a molecular weight of 36 kDa [
         <a href="#rid2">
          2,4,11
         </a>
         ]. Following the removal of the 21 amino acid signal peptide, the remaining 332 amino acids undergo glycosylation to produce a 95 kDa glycoprotein (
         <a class="graphic graphic_figure graphicRef62134" href="/z/d/graphic/62134.html" rel="external">
          figure 1
         </a>
         ). The glycoprotein is then released into the circulation with no apparent intracellular storage in the liver.
        </p>
        <p>
         TPO is an unusual hematopoietic growth factor in a number of ways:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It is much larger than most other regulators of blood cell production such as G-CSF (granulocyte colony-stimulating factor) and erythropoietin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It has an unusual structure in that the first 153 amino acids of the mature protein are 23 percent homologous with human erythropoietin (
         <a class="graphic graphic_figure graphicRef62134" href="/z/d/graphic/62134.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid12">
          12
         </a>
         ] and probably 50 percent similar if conservative amino acid substitutions are considered. This region also contains four cysteine residues just like those in erythropoietin and is highly conserved among different species. Despite these similarities, TPO does not bind the erythropoietin receptor and erythropoietin does not bind the TPO receptor.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Amino acids 154 to 332 comprise a novel sequence that contains six-N-linked glycosylation sites and is less well conserved among different species. Structure-function studies have demonstrated that the first 153 amino acids of the c-Mpl ligand are all that is required for its thrombopoietic effect in vitro [
         <a href="#rid2">
          2,4
         </a>
         ]; however, this truncated molecule has a markedly decreased circulatory half-life compared with the 20 to 40 hour half-life of the native protein [
         <a href="#rid13">
          13
         </a>
         ]. Presumably, the glycosylated second half of the molecule confers stability and prolongs the circulatory half-life. Similar carbohydrate sequences regulate the stability of erythropoietin [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The crystal structure of TPO has been determined and reveals an antiparallel four-helix bundle fold with two different binding sites for the TPO receptor. One has a binding constant for the TPO receptor of 3.3 x 10
         <sup>
          -9
         </sup>
         M and the other 1.1 x 10
         <sup>
          -6
         </sup>
         M [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          THROMBOPOIETIN GENE
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is a single copy of the gene for TPO (
         <em>
          THPO
         </em>
         ) on human chromosome 3q27-28 [
         <a href="#rid11">
          11,12,16
         </a>
         ]. The gene spans approximately 7 kb with seven exons, the first two of which are noncoding. The third exon contains part of the 5'-untranslated sequence and part of the signal peptide. The erythropoietin-like region is coded for by exons 4 to 7 and all of the carbohydrate domain is encoded by exon 7.
        </p>
        <p>
         Comparison with the gene for erythropoietin shows conservation of the boundaries of the coding exons except for the addition of the carbohydrate domain sequence in the final exon of the
         <em>
          THPO
         </em>
         gene. In addition to the functional mRNA encoded (TPO-1), two other nonfunctional mRNA sequences (TPO-2 and TPO-3) are present due to alternative splicing [
         <a href="#rid11">
          11,12
         </a>
         ].
        </p>
        <p>
         Studies in mice have challenged assumptions about whether hepatic TPO production is constitutive or induced. In mouse model studies, the Ashwell-Morell receptor (AMR) on hepatocytes can bind platelets that have lost sialic acids on their surface. This binding activates a signaling pathway that increases hepatic TPO mRNA and TPO production [
         <a href="#rid17">
          17
         </a>
         ]. This pathway might partially explain thrombocytosis seen in
         <em>
          JAK2
         </em>
         mutated myeloproliferative neoplasms; whether it plays any role in normal human physiology is unclear. Subsequent studies called this analysis into question by showing that it is hepatic Kupffer cells, not hepatocytes, that clear senescent platelets from the circulation [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          THROMBOPOIETIN RECEPTOR
         </span>
         <span class="headingEndMark">
          —
         </span>
         TPO acts through the TPO receptor, called c-Mpl. Prior to the identification of TPO, a murine myeloproliferative leukemia virus was identified that contained a retroviral oncogene,
         <strong>
          v-Mpl
         </strong>
         (ie,
         <strong>
          m
         </strong>
         yelo
         <strong>
          p
         </strong>
         roliferative
         <strong>
          l
         </strong>
         eukemia); this oncogene encoded the cytoplasmic portion of a membrane protein which had all the characteristics of a new hematopoietic growth factor receptor [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         When the full-length homolog (
         <strong>
          c-Mpl
         </strong>
         ) was cloned [
         <a href="#rid7">
          7
         </a>
         ], its mRNA was found to be present at significant levels primarily in platelets and megakaryocytes and in a small percentage of CD34+ cells (which are early hematopoietic precursors) [
         <a href="#rid20">
          20
         </a>
         ]. The identification of c-Mpl as the putative TPO receptor was further strengthened by the demonstration that the formation of megakaryocyte (Meg-CFC), but not myeloid (GM-CFC) or erythroid (E-BFU), precursors in bone marrow culture was decreased when synthesis of the c-Mpl protein was inhibited by the addition of c-Mpl antisense constructs [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         It is now known that the TPO receptor (c-Mpl) is present on platelets and megakaryocytes and, at a lesser density, on most other hematopoietic precursor cells. Studies with human platelets indicate the presence of approximately 56 ± 17 receptors per human platelet with an affinity of 163 ± 31 pmol/L [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         Upon binding to TPO, the receptor undergoes dimerization that results in a number of signal transduction events that prevent apoptosis, improve cell viability, promote growth, and possibly increase differentiation in megakaryocytes [
         <a href="#rid23">
          23
         </a>
         ]. In addition, binding to the receptor provides the major mechanism by which TPO is removed from the circulation by platelets and possibly megakaryocytes [
         <a href="#rid3">
          3,24-27
         </a>
         ]. After TPO binds to platelets, the receptor-ligand complex undergoes internalization and the bound thrombopoietin is degraded [
         <a href="#rid22">
          22,28
         </a>
         ]. The receptor is not re-expressed on the platelet surface [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          PHYSIOLOGY OF THROMBOPOIETIN
         </span>
         <span class="headingEndMark">
          —
         </span>
         Much has been learned about the normal physiology of TPO, its effects upon bone marrow precursor cells, megakaryocytes, and platelets, as well as regulation of its concentration [
         <a href="#rid30">
          30,31
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Effects on platelet production
         </span>
         <span class="headingEndMark">
          —
         </span>
         TPO is the only physiologically relevant regulator of platelet production; it acts to "amplify" the basal production rate of megakaryocytes and platelets. When TPO or its receptor have been "knocked-out" by homologous recombination in mice, the megakaryocyte and platelet mass are reduced to approximately 10 percent of normal, but the animals are healthy and do not spontaneously bleed (
         <a class="graphic graphic_figure graphicRef68869" href="/z/d/graphic/68869.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid32">
          32-34
         </a>
         ]. The neutrophil and erythrocyte counts are normal. In animals in which only one copy of the TPO gene (
         <em>
          THPO
         </em>
         ) has been deleted, the platelet count is reduced to approximately 65 percent of normal. Such TPO-deficient mice can increase their platelet count if treated with other thrombopoietic growth factors such as interleukin (IL)-6, IL-11, and stem cell factor (c-kit ligand) [
         <a href="#rid35">
          35
         </a>
         ]. However, neither endogenous IL-6 nor endogenous IL-11 appears to be responsible for the residual platelet production in these animals [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         Binding of TPO to its receptor prevents apoptosis of megakaryocytes [
         <a href="#rid37">
          37
         </a>
         ] and increases their number, size, and ploidy (see
         <a class="medical medical_review" href="/z/d/html/6672.html" rel="external">
          "Megakaryocyte biology and platelet production"
         </a>
         ). The rate of cellular maturation is probably also increased. These events are mediated via signal transduction pathways involving JAK, STAT, and other intracellular mediators (
         <a class="graphic graphic_figure graphicRef74891" href="/z/d/graphic/74891.html" rel="external">
          figure 3
         </a>
         ). Furthermore, the addition of TPO to CD34+ cells in culture results in the majority of cells becoming megakaryocytes and then shedding platelets [
         <a href="#rid38">
          38
         </a>
         ]. This last step, the shedding of platelets from megakaryocytes, does not require, and actually may be inhibited by, the presence of thrombopoietin [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         When TPO or its receptor have been "knocked-out" by homologous recombination in mice, the megakaryocyte and platelet mass are reduced to approximately 10 percent of normal, but the animals are healthy and do not spontaneously bleed (
         <a class="graphic graphic_figure graphicRef68869" href="/z/d/graphic/68869.html" rel="external">
          figure 2
         </a>
         ). The factors responsible for the residual platelet production in this setting are not well understood.
        </p>
        <p>
         A predictable response occurs after the daily administration of a recombinant form of TPO to baboons (
         <a class="graphic graphic_figure graphicRef59564 graphicRef72350" href="/z/d/graphic/59564.html" rel="external">
          figure 4A-B
         </a>
         ) [
         <a href="#rid40">
          40,41
         </a>
         ]. During the first four days of administration, bone marrow megakaryocyte ploidy rises to a maximum but there is no change in the platelet count. On day five, the platelet count begins to rise and does so at a dose-dependent rate. With continued administration of TPO, a dose-dependent plateau platelet count is attained on days 8 to 12. There is a log-linear relationship between the TPO dose and the plateau platelet count with the maximum response being a sixfold increase in the rate of platelet production. Upon stopping the TPO, the platelet count returns to its baseline over 10 days without a rebound thrombocytopenia.
        </p>
        <p>
         A similar time course and platelet response have been demonstrated after recombinant TPO administration to humans with no apparent toxicity [
         <a href="#rid42">
          42-44
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/6671.html" rel="external">
          "Clinical applications of thrombopoietic growth factors"
         </a>
         ). There is no effect on red or white blood cells.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Effects on platelet function
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to increasing the number of megakaryocytes and platelets, TPO can also affect the function of platelets. When TPO binds to its platelet receptor, it induces phosphorylation of the c-Mpl receptor and a number of other molecules in several different signal transduction pathways [
         <a href="#rid45">
          45-47
         </a>
         ]. Although TPO does not cause platelet activation directly, it reduces the threshold for activation by other platelet agonists such as ADP and collagen by 50 percent. It is unclear if this is a clinically relevant effect posing a risk for thrombosis. (See
         <a class="medical medical_review" href="/z/d/html/6671.html" rel="external">
          "Clinical applications of thrombopoietic growth factors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Effects on bone marrow precursor cells
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although TPO affects late cellular maturation events only in megakaryocytes, it and its receptor (c-Mpl) appear to play an important role in the regulation of the growth of early precursors of other lineages and even of the pluripotential stem cell [
         <a href="#rid48">
          48-51
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6672.html" rel="external">
          "Megakaryocyte biology and platelet production", section on 'Thrombopoietin (role in megakaryocyte maturation)'
         </a>
         .)
        </p>
        <p>
         Most evidence suggests that binding of TPO to c-Mpl enhances the survival and proliferation of already committed precursor cells, rather than a true stimulation of differentiation from stem cells. Homozygous knock-in mice, in which the gene for c-Mpl was replaced by a gene for a chimeric molecule consisting of the extracellular domain of c-Mpl and the cytoplasmic domain of the G-CSF receptor, have a normal platelet count [
         <a href="#rid52">
          52
         </a>
         ]. Since the intracellular domain of the G-CSF receptor can functionally replace the signaling activity of c-Mpl, this result suggests that thrombopoietin primarily affects cells already committed to the megakaryocyte lineage.
        </p>
        <p>
         When administered to animals, TPO increases bone marrow and peripheral blood megakaryocyte precursor cells (Meg-CFC), bone marrow megakaryocyte number and ploidy, and the platelet count. In addition, both erythroid and multipotential precursor cells are increased in the bone marrow and peripheral blood but without affecting the erythrocyte or neutrophil count.
        </p>
        <p>
         In animals made deficient in TPO or its receptor (c-Mpl), Meg-CFC are reduced by 90 to 95 percent as expected, and myeloid and erythroid precursor cells are reduced by 60 to 80 percent (
         <a class="graphic graphic_figure graphicRef79858" href="/z/d/graphic/79858.html" rel="external">
          figure 5
         </a>
         ) [
         <a href="#rid32">
          32,35
         </a>
         ]. The normal neutrophil and erythrocyte counts in these animals are presumably maintained by intact feedback mechanisms mediated by G-CSF and erythropoietin.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Regulation of circulating levels
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hepatic TPO production is usually constitutive; circulating levels are determined by the circulating platelet mass (
         <a class="graphic graphic_figure graphicRef78686" href="/z/d/graphic/78686.html" rel="external">
          figure 6
         </a>
         ). In contrast with the production of red blood cells, which is regulated by a system that senses hypoxia and alters the rate of transcription of the erythropoietin gene, there is no such "sensor" of the platelet mass [
         <a href="#rid3">
          3,24-26,53
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6672.html" rel="external">
          "Megakaryocyte biology and platelet production", section on 'TPO role in maintaining platelet count'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7161.html" rel="external">
          "Regulation of erythropoiesis", section on 'Hypoxia and EPO expression'
         </a>
         .)
        </p>
        <p>
         TPO mRNA is produced at the same rate in healthy and thrombocytopenic individuals and is reduced in patients with liver disease [
         <a href="#rid54">
          54
         </a>
         ]. TPO levels can be increased by the cytokine interleukin 6 (IL-6), as illustrated in the examples below. (See
         <a class="local">
          'Inflammatory disorders and ovarian cancer'
         </a>
         below.)
        </p>
        <p>
         There is no evidence for post-transcriptional regulation [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
         Once TPO is produced, circulating TPO levels are regulated by the volume of the total platelet mass. Platelets and megakaryocytes contain high affinity TPO (c-Mpl) receptors that bind and clear TPO from the circulation, directly determining the circulating TPO concentration [
         <a href="#rid22">
          22
         </a>
         ]. Evidence for this includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When platelet production is decreased, as in thrombocytopenia due to megakaryocytic hypoplasia, clearance of TPO is reduced and levels rise [
         <a href="#rid22">
          22,25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Plasma TPO concentrations fall after platelet transfusion [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         This sort of feedback system is not unusual in hematology. Both M-CSF and G-CSF are normally regulated primarily by the amount of circulating monocytes and neutrophils, respectively [
         <a href="#rid57">
          57
         </a>
         ]. It seems as if only erythropoietin has a true sensor of the circulating blood cell mass that in turn alters production of this hematopoietic growth factor.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          DISORDERS OF THROMBOPOIETIN AND ITS RECEPTOR
         </span>
         <span class="headingEndMark">
          —
         </span>
         Understanding of the physiology of TPO has led to consideration of a number of possible clinical disorders ranging from excess TPO production to decreased expression of the TPO receptor [
         <a href="#rid53">
          53
         </a>
         ]. Some of these postulated disorders have now been identified in humans or animals.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Familial thrombocythemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Familial thrombocythemia, also called hereditary or inherited thrombocythemia or thrombocytosis, is a rare disorder that is transmitted in an autosomal dominant pattern. This disorder results from activating mutations in the genes for TPO or c-Mpl or from mutations in the genes for other proteins [
         <a href="#rid58">
          58,59
         </a>
         ]. Mutations in the TPO or c-MPL genes do not appear to be involved in the much more common sporadic cases of essential thrombocythemia. (See
         <a class="medical medical_review" href="/z/d/html/4491.html" rel="external">
          "Clinical manifestations, pathogenesis, and diagnosis of essential thrombocythemia", section on 'Familial essential thrombocythemia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Liver failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Since the liver is the primary site of TPO production and the TPO gene is usually not inducible, TPO deficiency may be responsible (perhaps along with splenic sequestration) for the thrombocytopenia seen in patients with liver failure. Partial resection of the liver in animals results in a proportional decrease in the platelet count [
         <a href="#rid60">
          60
         </a>
         ] and plasma TPO concentrations appear to be inappropriately low in patients with cirrhosis [
         <a href="#rid61">
          61
         </a>
         ]. Upon liver transplantation into patients with liver failure, TPO levels rise and platelet counts return to normal levels [
         <a href="#rid62">
          62
         </a>
         ]. This observation has led to the suggestion that TPO treatment may be an effective therapy in patients with liver failure. (See
         <a class="medical medical_review" href="/z/d/html/6671.html" rel="external">
          "Clinical applications of thrombopoietic growth factors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Thrombocytopenia due to anti-thrombopoietin antibodies
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a clinical trial, administration of one recombinant form of TPO, PEG-rHuMGDF, caused the appearance of antibodies to the recombinant molecule in some subjects. The antibody cross-reacted with endogenous TPO and neutralized its activity. Since TPO is produced in a constitutive fashion, these patients developed TPO deficiency and severe amegakaryocytic thrombocytopenia [
         <a href="#rid63">
          63,64
         </a>
         ]. One other individual with amegakaryocytic thrombocytopenia was diagnosed with an anti-TPO antibody and no prior exposure to recombinant TPO. This patient had severe thrombocytopenia and improved following treatment with
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         A [
         <a href="#rid65">
          65
         </a>
         ]. Subsequently, many patients with apparent immune thrombocytopenia (ITP) have been screened; of 205 ITP patients screened, only one has been found to have an anti-TPO antibody as the genesis for the thrombocytopenia [
         <a href="#rid66">
          66
         </a>
         ]. Of 961 ITP patients on clinical trials with
         <a class="drug drug_general" data-topicid="9493" href="/z/d/drug information/9493.html" rel="external">
          romiplostim
         </a>
         , none were found to have neutralizing antibodies to TPO [
         <a href="#rid67">
          67
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4670.html" rel="external">
          "Hematologic manifestations of systemic lupus erythematosus", section on 'Thrombocytopenia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1816680727">
         <span class="h2">
          Thrombocytopenia due to anti-c-Mpl antibodies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Measurement of anti-c-Mpl antibodies is not standardized or clinically available. Several studies have suggested that anti-c-Mpl antibodies may be associated with thrombocytopenia due to inhibition of megakaryocyte growth. In one study, 8 out of 69 (11.6 percent) of patients with systemic lupus erythematosus and 7 out of 84 (8.3 percent) of patients with ITP had anti-c-Mpl antibodies in their serum; among 84 healthy controls, no anti-c-Mpl antibodies were present [
         <a href="#rid68">
          68
         </a>
         ]. Antibodies from some of these patients inhibited megakaryocyte growth in culture. Another study reported that 54 out of 187 (29 percent) ITP patients (but none of 59 healthy controls) had antibodies against c-Mpl; the antibody-positive patients appeared to have fewer megakaryocytes and platelets and less responsive disease [
         <a href="#rid69">
          69
         </a>
         ]. This area requires more study and validation of assay sensitivity and specificity before clinical significance is established.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Amegakaryocytic thrombocytopenia and absent TPO receptor
         </span>
         <span class="headingEndMark">
          —
         </span>
         Congenital amegakaryocytic thrombocytopenia (CAMT) is a rare disorder that presents with severe thrombocytopenia and absence of megakaryocytes in the bone marrow. Some of these patients are homozygous for mutations that produce an inactive TPO receptor (c-Mpl) leading to minimal platelet production similar to that seen in c-Mpl knockout mice [
         <a href="#rid70">
          70
         </a>
         ]. Some of these patients ultimately develop bone marrow aplasia, confirming the multipotential effect of TPO activity [
         <a href="#rid71">
          71,72
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Thrombocytosis and chromosomal defects
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of hematopoietic disorders associated with thrombocythemia or abnormal megakaryocyte formation have been associated with defects involving chromosome 3q [
         <a href="#rid73">
          73
         </a>
         ], and some myeloid leukemias associated with thrombocytosis have a characteristic rearrangement of chromosome 3q21 and 3q26 [
         <a href="#rid16">
          16
         </a>
         ]. Since the TPO gene is located on chromosome 3q27-28 [
         <a href="#rid11">
          11,12,16
         </a>
         ], it has been suggested that the TPO gene might be mediating these effects. However, closer analysis of these chromosome regions in these patients has not demonstrated involvement of the TPO gene [
         <a href="#rid16">
          16,74
         </a>
         ] and blood TPO levels have been normal. These findings suggest that other genes close to the TPO gene may be responsible for other aspects of megakaryocyte differentiation and growth. Patients with the 5q- syndrome often have pathogenic variants affecting the ribosomal protein gene
         <em>
          RPS14
         </em>
         (not in the gene for TPO or its receptor Mpl), with thrombocytosis attributed to haploinsufficiency of the microRNA genes miR-145 and miR-146a [
         <a href="#rid75">
          75,76
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4483.html" rel="external">
          "Cytogenetics, molecular genetics, and pathophysiology of myelodysplastic syndromes/neoplasms (MDS)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H475050833">
         <span class="h2">
          Myeloproliferative disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mutations in the TPO receptor (
         <em>
          MPL
         </em>
         exon 10) are found in &lt;5 percent of patients with either essential thrombocythemia or primary myelofibrosis, but not in patients with polycythemia vera. Overall survival of those with primary myelofibrosis with the
         <em>
          MPL
         </em>
         mutation is no different from patients carrying the
         <em>
          JAK2 V617F
         </em>
         mutation (8 and 11 years, respectively) but shorter than patients with the
         <em>
          CALR
         </em>
         mutation (21 years) [
         <a href="#rid77">
          77
         </a>
         ]. Overall survival of patients with essential thrombocythemia and the
         <em>
          MPL
         </em>
         mutation was no different from patients carrying either the
         <em>
          JAK2 V617F
         </em>
         or
         <em>
          CALR
         </em>
         mutations. The relative thrombotic risks associated with
         <em>
          MPL
         </em>
         mutation versus the
         <em>
          JAK2 V617F
         </em>
         or
         <em>
          CALR
         </em>
         mutations is unknown due to the low numbers of patients with the
         <em>
          MPL
         </em>
         mutation. (See
         <a class="medical medical_review" href="/z/d/html/4511.html" rel="external">
          "Overview of the myeloproliferative neoplasms", section on 'MPL mutations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H343295167">
         <span class="h2">
          Inflammatory disorders and ovarian cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inflammatory disorders can cause an increase in the levels of the cytokine interleukin-6 (IL-6). IL-6 has minimal effect on normal platelet production (in a mouse model, the levels in wild-type and IL-6 knockout animals were 1.16 x 10
         <sup>
          12
         </sup>
         and 0.90 x 10
         <sup>
          12
         </sup>
         cells/L, respectively); however, IL-6 may affect TPO production in pathologic settings and may increase platelet production [
         <a href="#rid78">
          78
         </a>
         ]. When inflammation was induced in these mice, hepatic TPO mRNA increased and plasma levels of IL-6 and TPO rose in the wild-type but not the IL-6-deficient animals; however, there was no increase in platelet count [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
         A study involving administration of IL-6 to six individuals with advanced cancer showed increased TPO levels in response to five days of continuous IL-6 infusion [
         <a href="#rid79">
          79
         </a>
         ]. Administration of IL-6 to mice induced thrombocytosis and was linked to increased hepatic TPO mRNA and plasma TPO levels; antibody neutralization of TPO eliminated the thrombocytosis [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
         In a separate study involving patients with ovarian cancer, thrombocytosis was associated with increased levels of IL-6 and TPO; neutralization of the IL-6 eliminated the thrombocytosis [
         <a href="#rid80">
          80
         </a>
         ]. In mice bearing these human ovarian tumors, the rise in platelet count was mediated by IL-6-induced hepatic TPO production.
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          ASSAYS FOR THROMBOPOIETIN
         </span>
         <span class="headingEndMark">
          —
         </span>
         Measurement of the circulating concentration of TPO may be clinically useful [
         <a href="#rid81">
          81-83
         </a>
         ]; commercial ELISA assays are available. Several conclusions may be made:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         TPO concentrations are increased 10 to 20-fold over normal in bone marrow failure states such as aplastic anemia or following myeloablative chemotherapy [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         TPO levels are only slightly elevated above normal in immune thrombocytopenia (ITP) at platelet counts comparable to those seen in states of bone marrow failure [
         <a href="#rid84">
          84
         </a>
         ]. The relatively normal plasma TPO concentration in ITP probably reflects enhanced TPO clearance by the increased mass of bone marrow megakaryocytes and by the increased flux of platelets through the circulation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         TPO levels are normal or slightly elevated in essential thrombocythemia [
         <a href="#rid85">
          85
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         TPO levels may allow the distinction between states of increased platelet production (normal TPO concentrations) versus decreased platelet production (elevated TPO concentrations) (
         <a class="graphic graphic_figure graphicRef115486" href="/z/d/graphic/115486.html" rel="external">
          figure 7
         </a>
         ) [
         <a href="#rid81">
          81,84
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         TPO levels may predict response to TPO receptor agonists in patients with ITP.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2367497">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          TPO production
         </strong>
         – Thrombopoietin (TPO), a 95 kDa glycoprotein (
         <a class="graphic graphic_figure graphicRef62134" href="/z/d/graphic/62134.html" rel="external">
          figure 1
         </a>
         ) primarily produced in the liver, is the physiologically relevant regulator of platelet production, amplifying the basal production rate of megakaryocytes and platelets. (See
         <a class="local">
          'Physiology of thrombopoietin'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          TPO function
         </strong>
         – TPO acts through its receptor (c-Mpl), present on platelets and megakaryocytes and, at a lesser density, on most other hematopoietic precursor cells. Binding of TPO to its receptor prevents apoptosis of megakaryocytes and increases their number, size, and ploidy. (See
         <a class="local">
          'Thrombopoietin receptor'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6672.html" rel="external">
          "Megakaryocyte biology and platelet production"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          TPO regulation
         </strong>
         – Hepatic TPO production is mostly constitutive; circulating levels are determined by the circulating platelet mass (
         <a class="graphic graphic_figure graphicRef78686" href="/z/d/graphic/78686.html" rel="external">
          figure 6
         </a>
         ). TPO production may be reduced in liver failure and increased by interleukin-6 (IL-6) in inflammatory states and cancer. (See
         <a class="local">
          'Regulation of circulating levels'
         </a>
         above and
         <a class="local">
          'Liver failure'
         </a>
         above and
         <a class="local">
          'Inflammatory disorders and ovarian cancer'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical disorders of TPO or c-Mpl
         </strong>
         – Disorders involving TPO or c-Mpl include the following. (See
         <a class="local">
          'Disorders of thrombopoietin and its receptor'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Familial thrombocythemia is a rare autosomal dominant disorder most commonly resulting from activating mutations in the genes for TPO or c-Mpl. (See
         <a class="medical medical_review" href="/z/d/html/4491.html" rel="external">
          "Clinical manifestations, pathogenesis, and diagnosis of essential thrombocythemia", section on 'Familial essential thrombocythemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Antibodies to TPO or c-Mpl may rarely cause thrombocytopenia, often associated with reduced numbers of bone marrow megakaryocytes. (See
         <a class="local">
          'Thrombocytopenia due to anti-thrombopoietin antibodies'
         </a>
         above and
         <a class="local">
          'Thrombocytopenia due to anti-c-Mpl antibodies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Congenital amegakaryocytic thrombocytopenia is a rare genetic disorder with severe thrombocytopenia and absence of bone marrow megakaryocytes. Some patients are homozygous for inactivating mutations of c-Mpl. (See
         <a class="medical medical_review" href="/z/d/html/7152.html" rel="external">
          "Aplastic anemia: Pathogenesis, clinical manifestations, and diagnosis", section on 'Abnormal thrombopoietin or its receptor'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hepatic TPO deficiency is a major cause of thrombocytopenia in patients with liver failure. (See
         <a class="medical medical_review" href="/z/d/html/13932.html" rel="external">
          "Hemostatic abnormalities in patients with liver disease", section on 'Thrombocytopenia and platelet dysfunction'
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Kato T, Ogami K, Shimada Y, et al. Purification and characterization of thrombopoietin. J Biochem 1995; 118:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994; 369:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A 1994; 91:11104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994; 77:1117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994; 369:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           KELEMEN E, CSERHATI I, TANOS B. Demonstration and some properties of human thrombopoietin in thrombocythaemic sera. Acta Haematol 1958; 20:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vigon I, Mornon JP, Cocault L, et al. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci U S A 1992; 89:5640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaushansky K. Thrombopoietin. N Engl J Med 1998; 339:746.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nomura S, Ogami K, Kawamura K, et al. Cellular localization of thrombopoietin mRNA in the liver by in situ hybridization. Exp Hematol 1997; 25:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qian S, Fu F, Li W, et al. Primary role of the liver in thrombopoietin production shown by tissue-specific knockout. Blood 1998; 92:2189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foster DC, Sprecher CA, Grant FJ, et al. Human thrombopoietin: gene structure, cDNA sequence, expression, and chromosomal localization. Proc Natl Acad Sci U S A 1994; 91:13023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gurney AL, Kuang WJ, Xie MH, et al. Genomic structure, chromosomal localization, and conserved alternative splice forms of thrombopoietin. Blood 1995; 85:981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hokom MM, Lacey D, Kinstler OB, et al. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood 1995; 86:4486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spivak JL, Hogans BB. The in vivo metabolism of recombinant human erythropoietin in the rat. Blood 1989; 73:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feese MD, Tamada T, Kato Y, et al. Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment. Proc Natl Acad Sci U S A 2004; 101:1816.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schnittger S, de Sauvage FJ, Le Paslier D, Fonatsch C. Refined chromosomal localization of the human thrombopoietin gene to 3q27-q28 and exclusion as the responsible gene for thrombocytosis in patients with rearrangements of 3q21 and 3q26. Leukemia 1996; 10:1891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grozovsky R, Begonja AJ, Liu K, et al. The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling. Nat Med 2015; 21:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li Y, Fu J, Ling Y, et al. Sialylation on O-glycans protects platelets from clearance by liver Kupffer cells. Proc Natl Acad Sci U S A 2017; 114:8360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Souyri M, Vigon I, Penciolelli JF, et al. A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell 1990; 63:1137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Debili N, Wendling F, Cosman D, et al. The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood 1995; 85:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Methia N, Louache F, Vainchenker W, Wendling F. Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood 1993; 82:1395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li J, Xia Y, Kuter DJ. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. Br J Haematol 1999; 106:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaushansky K. Thrombopoietin: the primary regulator of platelet production. Blood 1995; 86:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuter DJ. Thrombopoietin: Biology and Clinical Applications. Oncologist 1996; 1:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuter DJ. Thrombopoietin: biology, clinical applications, role in the donor setting. J Clin Apher 1996; 11:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 1995; 85:2720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fielder PJ, Hass P, Nagel M, et al. Human platelets as a model for the binding and degradation of thrombopoietin. Blood 1997; 89:2782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fielder PJ, Gurney AL, Stefanich E, et al. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 1996; 87:2154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saur SJ, Sangkhae V, Geddis AE, et al. Ubiquitination and degradation of the thrombopoietin receptor c-Mpl. Blood 2010; 115:1254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med 2006; 354:2034.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuter DJ. Milestones in understanding platelet production: a historical overview. Br J Haematol 2014; 165:248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexander WS, Roberts AW, Nicola NA, et al. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood 1996; 87:2162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gurney AL, Carver-Moore K, de Sauvage FJ, Moore MW. Thrombocytopenia in c-mpl-deficient mice. Science 1994; 265:1445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Sauvage FJ, Carver-Moore K, Luoh SM, et al. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med 1996; 183:651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carver-Moore K, Broxmeyer HE, Luoh SM, et al. Low levels of erythroid and myeloid progenitors in thrombopoietin-and c-mpl-deficient mice. Blood 1996; 88:803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gainsford T, Nandurkar H, Metcalf D, et al. The residual megakaryocyte and platelet production in c-mpl-deficient mice is not dependent on the actions of interleukin-6, interleukin-11, or leukemia inhibitory factor. Blood 2000; 95:528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zauli G, Vitale M, Falcieri E, et al. In vitro senescence and apoptotic cell death of human megakaryocytes. Blood 1997; 90:2234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi ES, Nichol JL, Hokom MM, et al. Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional. Blood 1995; 85:402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi ES, Hokom MM, Chen JL, et al. The role of megakaryocyte growth and development factor in terminal stages of thrombopoiesis. Br J Haematol 1996; 95:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harker LA, Marzec UM, Hunt P, et al. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood 1996; 88:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harker LA, Hunt P, Marzec UM, et al. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood 1996; 87:1833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Basser RL, Rasko JE, Clarke K, et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 1996; 348:1279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuter DJ, Goodnough LT, Romo J, et al. Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood 2001; 98:1339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004; 76:628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen J, Herceg-Harjacek L, Groopman JE, Grabarek J. Regulation of platelet activation in vitro by the c-Mpl ligand, thrombopoietin. Blood 1995; 86:4054.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kubota Y, Arai T, Tanaka T, et al. Thrombopoietin modulates platelet activation in vitro through protein-tyrosine phosphorylation. Stem Cells 1996; 14:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montrucchio G, Brizzi MF, Calosso G, et al. Effects of recombinant human megakaryocyte growth and development factor on platelet activation. Blood 1996; 87:2762.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaushansky K, Lin N, Grossmann A, et al. Thrombopoietin expands erythroid, granulocyte-macrophage, and megakaryocytic progenitor cells in normal and myelosuppressed mice. Exp Hematol 1996; 24:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaushansky K. Thrombopoietin and the hematopoietic stem cell. Blood 1998; 92:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solar GP, Kerr WG, Zeigler FC, et al. Role of c-mpl in early hematopoiesis. Blood 1998; 92:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood 2014; 123:1818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stoffel R, Ziegler S, Ghilardi N, et al. Permissive role of thrombopoietin and granulocyte colony-stimulating factor receptors in hematopoietic cell fate decisions in vivo. Proc Natl Acad Sci U S A 1999; 96:698.
          </a>
         </li>
         <li class="breakAll">
          Kuter DJ. The regulation of platelet production. In: Thrombosis and Thrombopoietins: Molecular, Cellular, Preclinical and Clinical Biology, Kuter DJ, Hunt P, Sheridan W, et al. (Eds), Humana Press, Totowa 1997. p.377.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stoffel R, Wiestner A, Skoda RC. Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood 1996; 87:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang C, Li YC, Kuter DJ. The physiological response of thrombopoietin (c-Mpl ligand) to thrombocytopenia in the rat. Br J Haematol 1999; 105:478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheding S, Bergmann M, Shimosaka A, et al. Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivo. Transfusion 2002; 42:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cairo MS, Suen Y, Sender L, et al. Circulating granulocyte colony-stimulating factor (G-CSF) levels after allogeneic and autologous bone marrow transplantation: endogenous G-CSF production correlates with myeloid engraftment. Blood 1992; 79:1869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiestner A, Padosch SA, Ghilardi N, et al. Hereditary thrombocythaemia is a genetically heterogeneous disorder: exclusion of TPO and MPL in two families with hereditary thrombocythaemia. Br J Haematol 2000; 110:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiestner A, Schlemper RJ, van der Maas AP, Skoda RC. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nat Genet 1998; 18:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siemensma NP, Bathal PS, Penington DG. The effect of massive liver resection on platelet kinetics in the rat. J Lab Clin Med 1975; 86:817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peck-Radosavljevic M, Zacherl J, Meng YG, et al. Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver? J Hepatol 1997; 27:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peck-Radosavljevic M, Wichlas M, Zacherl J, et al. Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood 2000; 95:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Basser RL, O'Flaherty E, Green M, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 2002; 99:2599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98:3241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shiozaki H, Miyawaki S, Kuwaki T, et al. Autoantibodies neutralizing thrombopoietin in a patient with amegakaryocytic thrombocytopenic purpura. Blood 2000; 95:2187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aledort LM, Hayward CP, Chen MG, et al. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol 2004; 76:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mytych DT, Park JK, Kim J, et al. Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global postmarketing registry. Br J Haematol 2020; 190:923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuwana M, Okazaki Y, Kajihara M, et al. Autoantibody to c-Mpl (thrombopoietin receptor) in systemic lupus erythematosus: relationship to thrombocytopenia with megakaryocytic hypoplasia. Arthritis Rheum 2002; 46:2148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jing FM, Zhang XL, Meng FL, et al. Anti-c-Mpl antibodies in immune thrombocytopenia suppress thrombopoiesis and decrease response to rhTPO. Thromb Res 2018; 170:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heckl D, Wicke DC, Brugman MH, et al. Lentiviral gene transfer regenerates hematopoietic stem cells in a mouse model for Mpl-deficient aplastic anemia. Blood 2011; 117:3737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ihara K, Ishii E, Eguchi M, et al. Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proc Natl Acad Sci U S A 1999; 96:3132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van den Oudenrijn S, Bruin M, Folman CC, et al. Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia. Br J Haematol 2000; 110:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pinto MR, King MA, Goss GD, et al. Acute megakaryoblastic leukaemia with 3q inversion and elevated thrombopoietin (TSF): an autocrine role for TSF? Br J Haematol 1985; 61:687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bouscary D, Fontenay-Roupie M, Chretien S, et al. Thrombopoietin is not responsible for the thrombocytosis observed in patients with acute myeloid leukemias and the 3q21q26 syndrome. Br J Haematol 1995; 91:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boultwood J, Pellagatti A, Wainscoat JS. 5q- syndrome. Curr Pharm Des 2012; 18:3180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boultwood J, Pellagatti A, McKenzie AN, Wainscoat JS. Advances in the 5q- syndrome. Blood 2010; 116:5803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369:2379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burmester H, Wolber EM, Freitag P, et al. Thrombopoietin production in wild-type and interleukin-6 knockout mice with acute inflammation. J Interferon Cytokine Res 2005; 25:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaser A, Brandacher G, Steurer W, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood 2001; 98:2720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stone RL, Nick AM, McNeish IA, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012; 366:610.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Makar RS, Zhukov OS, Sahud MA, Kuter DJ. Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists. Am J Hematol 2013; 88:1041.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuter DJ, Meibohm A, Lopez A. TPO concentrations and response to romiplostim. Am J Hematol 2014; 89:1155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Samkari H, Kuter DJ. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia. Am J Hematol 2018; 93:1501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emmons RV, Reid DM, Cohen RL, et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996; 87:4068.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horikawa Y, Matsumura I, Hashimoto K, et al. Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia. Blood 1997; 90:4031.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6673 Version 25.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8537317" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Purification and characterization of thrombopoietin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8202154" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7972018" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8020099" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8202158" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13616931" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Demonstration and some properties of human thrombopoietin in thrombocythaemic sera.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1608974" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9731092" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Thrombopoietin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9216731" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Cellular localization of thrombopoietin mRNA in the liver by in situ hybridization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9731084" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Primary role of the liver in thrombopoietin production shown by tissue-specific knockout.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7809166" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Human thrombopoietin: gene structure, cDNA sequence, expression, and chromosomal localization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7849319" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Genomic structure, chromosomal localization, and conserved alternative splice forms of thrombopoietin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8541537" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2462945" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : The in vivo metabolism of recombinant human erythropoietin in the rat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14769915" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8946927" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Refined chromosomal localization of the human thrombopoietin gene to 3q27-q28 and exclusion as the responsible gene for thrombocytosis in patients with rearrangements of 3q21 and 3q26.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25485912" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28716912" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Sialylation on O-glycans protects platelets from clearance by liver Kupffer cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2175677" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7529061" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7689867" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10460590" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7605981" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Thrombopoietin: the primary regulator of platelet production.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10387974" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Thrombopoietin: Biology and Clinical Applications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8915820" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Thrombopoietin: biology, clinical applications, role in the donor setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7742532" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9108396" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Human platelets as a model for the binding and degradation of thrombopoietin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8630374" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19880496" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Ubiquitination and degradation of the thrombopoietin receptor c-Mpl.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16687716" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Lineage-specific hematopoietic growth factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24528208" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Milestones in understanding platelet production: a historical overview.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8630375" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8073287" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Thrombocytopenia in c-mpl-deficient mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8627177" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8704234" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Low levels of erythroid and myeloid progenitors in thrombopoietin-and c-mpl-deficient mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10627458" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The residual megakaryocyte and platelet production in c-mpl-deficient mice is not dependent on the actions of interleukin-6, interleukin-11, or leukemia inhibitory factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9310474" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : In vitro senescence and apoptotic cell death of human megakaryocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7529062" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8904874" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The role of megakaryocyte growth and development factor in terminal stages of thrombopoiesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8695799" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8634430" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8909381" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11520780" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Thrombopoietin therapy increases platelet yields in healthy platelet donors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15592334" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7492761" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Regulation of platelet activation in vitro by the c-Mpl ligand, thrombopoietin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8843545" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Thrombopoietin modulates platelet activation in vitro through protein-tyrosine phosphorylation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8639892" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Effects of recombinant human megakaryocyte growth and development factor on platelet activation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8641351" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Thrombopoietin expands erythroid, granulocyte-macrophage, and megakaryocytic progenitor cells in normal and myelosuppressed mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9639491" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Thrombopoietin and the hematopoietic stem cell.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9639492" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Role of c-mpl in early hematopoiesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24345753" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9892696" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Permissive role of thrombopoietin and granulocyte colony-stimulating factor receptors in hematopoietic cell fate decisions in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9892696" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Permissive role of thrombopoietin and granulocyte colony-stimulating factor receptors in hematopoietic cell fate decisions in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8555478" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10233424" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : The physiological response of thrombopoietin (c-Mpl ligand) to thrombocytopenia in the rat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11961237" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1373092" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Circulating granulocyte colony-stimulating factor (G-CSF) levels after allogeneic and autologous bone marrow transplantation: endogenous G-CSF production correlates with myeloid engraftment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10930985" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Hereditary thrombocythaemia is a genetically heterogeneous disorder: exclusion of TPO and MPL in two families with hereditary thrombocythaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9425899" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1185040" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : The effect of massive liver resection on platelet kinetics in the rat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9252085" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10648388" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11895799" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11719360" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Thrombocytopenia caused by the development of antibodies to thrombopoietin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10755821" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Autoantibodies neutralizing thrombopoietin in a patient with amegakaryocytic thrombocytopenic purpura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15224353" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32311075" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global postmarketing registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12209520" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Autoantibody to c-Mpl (thrombopoietin receptor) in systemic lupus erythematosus: relationship to thrombocytopenia with megakaryocytic hypoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30199786" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Anti-c-Mpl antibodies in immune thrombocytopenia suppress thrombopoiesis and decrease response to rhTPO.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21289307" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Lentiviral gene transfer regenerates hematopoietic stem cells in a mouse model for Mpl-deficient aplastic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10077649" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10971406" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4084458" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Acute megakaryoblastic leukaemia with 3q inversion and elevated thrombopoietin (TSF): an autocrine role for TSF?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8547088" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Thrombopoietin is not responsible for the thrombocytosis observed in patients with acute myeloid leukemias and the 3q21q26 syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22571696" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : 5q- syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20733155" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Advances in the 5q- syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24325356" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Somatic mutations of calreticulin in myeloproliferative neoplasms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16022585" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Thrombopoietin production in wild-type and interleukin-6 knockout mice with acute inflammation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11675343" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22335738" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Paraneoplastic thrombocytosis in ovarian cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23913253" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25132329" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : TPO concentrations and response to romiplostim.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30187942" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8639762" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9354672" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
